Literature DB >> 3033178

Prevention of glomerular capillary hypertension in experimental diabetes mellitus obviates functional and structural glomerular injury.

B R Dunn, R Zatz, H G Rennke, T W Meyer, S Anderson, B M Brenner.   

Abstract

Streptozotocin-diabetic rats kept moderately hyperglycaemic by daily injections of ultralente insulin for 4-6 weeks (group DM) demonstrated a higher glomerular transcapillary hydraulic pressure gradient (delta P), glomerular plasma flow rate and single-nephron glomerular filtration rate (GFR) than was observed in age- and weight-matched non-diabetic controls (group C). This rise in delta P was prevented by therapy with the angiotensin I converting enzyme inhibitor enalapril (15 mg/l drinking water, group DM + E) even though glomerular hyperperfusion and hyperfiltration persisted. Fourteen months after induction of diabetes, animals in group DM displayed high levels of albuminuria and an increased incidence of focal glomerular sclerosis; treatment with enalapril maintained these parameters at levels which did not differ from those observed in group C. We conclude that prevention of glomerular capillary hypertension with enalapril therapy obviates functional and structural glomerular injury in experimental diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3033178

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  10 in total

Review 1.  ACE inhibitors in the prevention and therapy of diabetic nephropathy. What is their role?

Authors:  C C Kelleher
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 2.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 3.  The next generation of therapeutics for chronic kidney disease.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Nat Rev Drug Discov       Date:  2016-05-27       Impact factor: 84.694

4.  Impact of obesity on renal structure and function in the presence and absence of hypertension: evidence from melanocortin-4 receptor-deficient mice.

Authors:  Jussara M do Carmo; Lakshmi S Tallam; John V Roberts; Elizabeth L Brandon; John Biglane; Alexandre A da Silva; John E Hall
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-15       Impact factor: 3.619

5.  Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats.

Authors:  H Wehner; G Nelischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

6.  Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy.

Authors:  T Baba; T Tomiyama; S Murabayashi; K Takebe
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction.

Authors:  B Murali; Dhananjay N Umrani; Ramesh K Goyal
Journal:  Mol Cell Biochem       Date:  2003-07       Impact factor: 3.396

8.  Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier.

Authors:  Jan Michael Williams; Mukut Sharma; Siddam Anjaiahh; John R Falck; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2007-05-16

Review 9.  Proteinuria in diabetic nephropathy: treatment and evolution.

Authors:  Ruth C Campbell; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430

Review 10.  Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.

Authors:  Robert D Toto
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.